Ipamorelin Slows Cognitive Decline in American Males with MCI: A 5-Year Study
Reading Time: 2 minutes Introduction Cognitive decline, particularly in the context of mild cognitive impairment (MCI), poses a significant challenge to the aging population. As the prevalence of MCI increases, the search for effective interventions becomes ever more critical. Ipamorelin, a selective growth hormone secretagogue, has emerged as a promising candidate in this arena. This article delves into a five-year neurological study focused on American males, exploring the impact of Ipamorelin on cognitive function and its potential to alter the trajectory of cognitive decline. Study Design and Methodology The study involved a cohort of 200 American males aged 50 to 70 years, all diagnosed...



